Director/PDMR Shareholding

RNS Number : 2974U

GlaxoSmithKline PLC

16 January 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sir Andrew Witty
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 406.772 (personal contribution) £15.66 406.759 (personal contribution) £15.66 203.865 (personal contribution) £15.66 203.865 (personal contribution) £15.66 510.713 (personal contribution) £15.66 406.772 (matching shares) £15.66 406.759 (matching shares) £15.66 203.865 (matching shares) £15.66 203.865 (matching shares) £15.66 510.713 (matching shares)
d)	Aggregated information Aggregated volume Price	3,463.948 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	CEO Designate
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 89.065 (personal contribution) £15.66 89.065 (personal contribution) £15.66 71.015 (personal contribution) £15.66 71.015 (personal contribution) £15.66 175.863 (personal contribution) £15.66 175.850 (personal contribution) £15.66 89.065 (matching shares) £15.66 89.065 (matching shares) £15.66 71.015 (matching shares) £15.66 71.015 (matching shares) £15.66 175.863 (matching shares) £15.66 175.850 (matching shares)
d)	Aggregated information Aggregated volume Price	1,343.746 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 79.620 (personal contribution) £15.66 79.607 (personal contribution) £15.66 52.007 (personal contribution) £15.66 52.007 (personal contribution) £15.66 119.484 (personal contribution) £15.66 79.620 (matching shares) £15.66 79.607 (matching shares) £15.66 52.007 (matching shares) £15.66 52.007 (matching shares) £15.66 119.484 (matching shares)
d)	Aggregated information Aggregated volume Price	765.45 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 192.213 (personal contribution) £15.66 76.874 (personal contribution) £15.66 99.193 (personal contribution) £15.66 99.180 (personal contribution) £15.66 232.242 (personal contribution) £15.66 232.229 (personal contribution) £15.66 192.213 (matching shares) £15.66 76.874 (matching shares) £15.66 99.193 (matching shares) £15.66 99.180 (matching shares) £15.66 232.242 (matching shares) £15.66 232.229 (matching shares)
d)	Aggregated information Aggregated volume Price	1,863.862 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 36.414 (personal contribution) £15.66 36.414 (personal contribution) £15.66 85.869 (personal contribution) £15.66 85.869 (personal contribution) £15.66 36.414 (matching shares) £15.66 36.414 (matching shares) £15.66 85.869 (matching shares) £15.66 85.869 (matching shares)
d)	Aggregated information Aggregated volume Price	489.132 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S A Hussain
b)	Position/status	President, Global Pharmaceuticals
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 116.783 (personal contribution) £15.66 171.654 (personal contribution) £15.66 202.916 (personal contribution) £15.66 202.916 (personal contribution) £15.66 116.783 (matching shares) £15.66 171.654 (matching shares) £15.66 202.916 (matching shares) £15.66 202.916 (matching shares)
d)	Aggregated information Aggregated volume Price	1,388.538 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 72.618 (personal contribution) £15.66 72.605 (personal contribution) £15.66 58.351 (personal contribution) £15.66 58.351 (personal contribution) £15.66 109.284 (personal contribution) £15.66 109.284 (personal contribution) £15.66 72.618 (matching shares) £15.66 72.605 (matching shares) £15.66 58.351 (matching shares) £15.66 58.351 (matching shares) £15.66 109.284 (matching shares) £15.66 109.284 (matching shares)
d)	Aggregated information Aggregated volume Price	960.986 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr M M Slaoui
b)	Position/status	Chairman, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $39.01 125.340 (personal contribution) $39.01 125.327 (personal contribution) $39.01 78.047 (personal contribution) $39.01 78.047 (personal contribution) $39.01 128.475 (personal contribution) $39.01 128.475 (personal contribution) $39.01 125.340 (matching shares) $39.01 125.327 (matching shares) $39.01 78.047 (matching shares) $39.01 78.047 (matching shares) $39.01 128.475 (matching shares) $39.01 128.475 (matching shares)
d)	Aggregated information Aggregated volume Price	1,327.422 $39.01
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 90.103 (personal contribution) £15.66 78.542 (personal contribution) £15.66 78.530 (personal contribution) £15.66 159.879 (personal contribution) £15.66 159.879 (personal contribution) £15.66 90.103 (matching shares) £15.66 78.542 (matching shares) £15.66 78.530 (matching shares) £15.66 159.879 (matching shares) £15.66 159.879 (matching shares)
d)	Aggregated information Aggregated volume Price	1,133.866 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	SVP, Communications & Government Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 54.266 (personal contribution) £15.66 53.347 (personal contribution) £15.66 97.819 (personal contribution) £15.66 54.266 (matching shares) £15.66 53.347 (matching shares) £15.66 97.819 (matching shares)
d)	Aggregated information Aggregated volume Price	410.864 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D E Troy
b)	Position/status	SVP & General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $39.01 50.726 (personal contribution) $39.01 50.726 (personal contribution) $39.01 40.386 (personal contribution) $39.01 40.386 (personal contribution) $39.01 90.932 (personal contribution) $39.01 90.932 (personal contribution) $39.01 50.726 (matching shares) $39.01 50.726  (matching shares) $39.01 40.386  (matching shares) $39.01 40.386  (matching shares) $39.01 90.932  (matching shares) $39.01 90.932  (matching shares)
d)	Aggregated information Aggregated volume Price	728.176 $39.01
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P J T Vallance
b)	Position/status	President, Pharmaceuticals R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.66 161.014 (personal contribution) £15.66 161.001 (personal contribution) £15.66 115.614 (personal contribution) £15.66 115.614 (personal contribution) £15.66 188.068 (personal contribution) £15.66 188.068 (personal contribution) £15.66 161.014 (matching shares) £15.66 161.001  (matching shares) £15.66 115.614 (matching shares) £15.66 115.614 (matching shares) £15.66 188.068 (matching shares) £15.66 188.068 (matching shares)
d)	Aggregated information Aggregated volume Price	1,858.758 £15.66
e)	Date of the transaction	2017-01-12
f)	Place of the transaction	n/a

 

END

 

 

DSHVQLFFDFFLBBB